An FDA advisory panel is scheduled Thursday to consider if the heart
drug BiDil should be approved as the first drug targeted to a specific
racial group. Supporters of the drug produced by NitroMed cite a study
of 1,050 black heart-failure patients that showed it significantly
reduced death and hospitalization, but some scientists question whether
BiDil should be used just for one group and say it probably has
benefits for the general population.